Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ADK | P55263 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CDA | P32320 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.44 |
| ▸ | PYGB | P11216 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15955793 | 1.00 | NPC1 (0.49) | NPC1RAB9ATSHRADKCA1 | |
| SCHEMBL769262 | 0.80 | ADORA1 (0.45) | MAPTCDA | |
| SCHEMBL14403360 | 0.78 | ADK (0.51) | NPC1RAB9ATSHRADKCA1 | |
| SCHEMBL12171751 | 0.78 | ADK (0.51) | NPC1RAB9ATSHRADKCA1 | |
| SCHEMBL25084035 | 0.77 | IGF2R (0.41) | NPC1RAB9ATSHRCA1CA2 | |
| SCHEMBL4901149 | 0.77 | ADK (0.56) | TSHRADKCA1CA2 | |
| SCHEMBL7905414 | 0.75 | TSHR (0.59) | NPC1RAB9ATSHRADKCA1 | |
| SCHEMBL5063261 | 0.75 | TSHR (0.43) | NPC1RAB9ATSHRADKCA1 | |
| SCHEMBL4875548 | 0.75 | ADK (0.43) | NPC1RAB9ATSHRADKCA1 | |
| SCHEMBL7151149 | 0.75 | NPC1 (0.74) | NPC1RAB9ATSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449570-B2 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7291603-B2 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166926-A1 | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases | NSUN2, UPF1, NSUN3 | NPC1 333/4885RAB9A 2042/4885TSHR 3690/4885 |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | NPC1 257/4885RAB9A 2040/4885TSHR 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.